Monthly Features

CROs juggle proprietary and commercial systems

Tuesday, March 15, 2016

Third-party vendors have come to dominate the clinical trial technology sector, which was led by CROs a decade ago. At the same time, many large CROs continue to invest in technology solutions to differentiate their services and offer greater efficiencies in clinical development processes.

[Read More]

Slow to negative growth in select emerging markets

Tuesday, March 1, 2016

A few years ago, Latin America and India were considered among the most promising emerging markets for conducting industry-sponsored clinical trials. Dramatic increases were predicted for both regions, and investigative sites anticipated an influx of new work. Unfortunately, growth in these markets has fallen far short of expectations.

[Read More]

Top issues facing ClinOps executives

Tuesday, December 1, 2015

Never before have operating conditions for clinical studies been more difficult. Clinical operations groups face growing pressure to get drugs to market faster while improving efficiencies and study quality. Development costs continue to rise. At the same time, the logistics of conducting a clinical trial have become more complex in the increasingly competitive and regulated environment.

[Read More]

Is there really a shortage of study volunteers?

Saturday, August 1, 2015

Patient recruitment remains one of the biggest challenges facing the clinical research enterprise today. Forward-thinking industry leaders recognize the need for rethinking the common view that pa­tient recruitment is difficult primarily due to a shortage of study volunteers. Instead, these experts believe the industry needs to focus the discussion on practices that limit access to clinical trials and how to build support sys­tems needed to better engage patient commu­nities and the public in clinical research.

[Read More]

Pharma industry improves its tarnished reputation

Monday, June 15, 2015

The reputation of the pharmaceutical industry—historically not much better than that of the oil or tobacco industries—has stabilized in recent years. And public views about clinical research have improved significantly. Yet overall, the level of trust in pharmaceutical companies remains low.

[Read More]